Gastroenterology

2017 ◽  
pp. 242-291
Author(s):  
Ian B. Wilkinson ◽  
Tim Raine ◽  
Kate Wiles ◽  
Anna Goodhart ◽  
Catriona Hall ◽  
...  
Keyword(s):  
Fatty Liver Disease ◽  
Sclerosing Cholangitis ◽  
Primary Biliary Cholangitis ◽  
Liver Tumours ◽  
Alcoholic Fatty Liver ◽  
Ulcer Disease ◽  
A1at Deficiency ◽  
Irritable Bowel ◽  
Upper Gastrointestinal ◽  
Alcoholic Fatty Liver Disease

This chapter explores gastroenterology, including healthy, enjoyable eating, mouth observations, endoscopy and biopsy, dysphagia, nausea and vomiting, dyspepsia and peptic ulcer disease, gastro-oesophageal reflux disease (GORD), upper gastrointestinal bleeding, diarrhoea, constipation, ulcerative colitis (UC), Crohn’s disease, gastrointestinal malabsorption, Coeliac disease, irritable bowel syndrome (IBS), nutritional disorders, chronic pancreatitis, carcinoma of the pancreas, carcinoid tumours, jaundice, liver failure, cirrhosis, viral hepatitis, alcoholism, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), non-alcoholic fatty liver disease (NAFLD), Wilson’s disease/hepatolenticular degeneration, liver tumours, hereditary haemochromatosis (HH), and α‎1-antitrypsin (A1AT) deficiency.

scholarly journals Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?

2021 ◽  
Vol 13 (12) ◽  
pp. 1816-1827
Author(s):  
Huw Purssell ◽  
Peter J Whorwell ◽  
Varinder S Athwal ◽  
Dipesh H Vasant
Keyword(s):  
Irritable Bowel Syndrome ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Irritable Bowel ◽  
Alcoholic Fatty Liver Disease

scholarly journals Etiología de la cirrosis: los cambios epidemiológicos entre los períodos 1995-2002 y 2010-2017

2020 ◽  
Author(s):  
Daniel S García ◽  
Yamila Martínez Artola ◽  
Daniel A Poncino ◽  
María Ferreira Rubino ◽  
Rafael Escobar ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Hereditary Hemochromatosis ◽  
Hepatic Function ◽  
Primary Biliary Cholangitis ◽  
Alcoholic Fatty Liver ◽  
Current Period ◽  
Asymptomatic Stage ◽  
Alcoholic Fatty Liver Disease

The aim of the study was to describe the clinical characteristics and the proportion of the different etiologies of liver cirrhosis (LC) diagnosed between 2010 and 2017 and compare with the period 1995-2002. In the 2010-2017 period, 260 patients with LC were diagnosed. The etiologies were: Alcohol 94 patients (36.1%), chronic hepatitis C (HCV) 87 (33.4%), non-alcoholic fatty liver disease (NAFLD) 35 (13.4%), primary biliary cholangitis 13 (PBC) (5.0%), autoimmune hepatitis (AIH) 12 (4.6%), chronic hepatitis B 7 (2.7%), hereditary hemochromatosis 1 (0.4%) and cryptogenic 11 (4.2%). Compared with the 1995-2002 period that included 252 patients, there was a significant reduction in the number and percentage of LC by alcohol and cryptogenic and an increase in those associated with NAFLD and AIH. In comparison with the period 1995-2002, a better hepatic function of LC was observed in general, and especially in those related to alcohol and HCV. However, in the 2010-2017 period, LC by alcohol compared with those associated with HCV and NAFLD showed a significantly greater deterioration in liver function. The main etiologies of LC are alcohol and HCV followed by NAFLD and autoimmune liver diseases (PBC and AIH). Although in the current period LC was diagnosed at earlier stages, LC by alcohol presented a low percentage of initial diagnoses in the asymptomatic stage.

scholarly journals Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1358 ◽  
Author(s):  
Aline Gottlieb ◽  
Ali Canbay
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Bile Acids ◽  
Fatty Liver Disease ◽  
The Body ◽  
Farnesoid X Receptor ◽  
Bile Acid Metabolism ◽  
Primary Biliary Cholangitis ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a complex disease, affecting not just the liver, but also all other organs in the body. Despite an increasing amount of people worldwide developing NAFLD and having it progress to non-alcoholic steatohepatitis (NASH) and potentially cirrhosis, there is still no approved therapy. Therefore, huge efforts are being made to find and develop a successful treatment. One of the special interests is understanding the liver–gut axis and especially the role of bile acids in the progression of NAFLD. Farnesoid X receptor (FXR)-agonists have been approved und used in other liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), and have shown signs of being able to decrease inflammation and potentially steatosis. This review will mainly focus on targets/ligands that play an important role in bile acid metabolism and give an overview of ongoing clinical as well as pre-clinical trials. With the complexity of the issue, we did not aim at giving a complete review, rather highlighting important targets and potential treatments that could be approved for NAFLD/NASH treatment within the next few years.

Prevention of gastrointestinal disease

2018 ◽  
Author(s):  
Satish Keshav ◽  
Alexandra Kent
Keyword(s):  
Liver Disease ◽  
Fatty Liver Disease ◽  
Gastrointestinal Disease ◽  
Oesophageal Adenocarcinoma ◽  
Hepatic Cancer ◽  
Alcoholic Fatty Liver ◽  
Ulcer Disease ◽  
Inflammatory Bowel ◽  
Considerable Morbidity ◽  
Alcoholic Fatty Liver Disease

Disease prevention is usually directed where there is considerable morbidity or mortality, and etiological factors that can be controlled, treated, or reduced. The greatest morbidity and mortality from gastrointestinal disease is related to infectious diarrhoea and gastrointestinal cancer, both of which can be prevented. Smoking has been closely associated with oesophageal, gastric, and liver cancer and also has a significant effect in inflammatory bowel disease. In addition, alcohol consumption and viral hepatitis are preventable causes of liver disease, liver failure, and hepatic cancer. This chapter addresses the prevention of gastrointestinal disease, focusing on alcohol, smoking, peptic ulcer disease, colorectal cancer, oesophageal adenocarcinoma, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, and gastrointestinal infection.

scholarly journals The impact of primary biliary cholangitis on non-alcoholic fatty liver disease

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Daniel Iluz-Freundlich ◽  
Julia Uhanova ◽  
Micah Grubert Van Iderstine ◽  
Gerald Y. Minuk
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Primary Biliary Cholangitis ◽  
Alcoholic Fatty Liver ◽  
The Impact ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document